Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05438420
Title Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Qurient Co., Ltd.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Southern California RECRUITING Los Angeles California 90033 United States Details
Norton Cancer Institute RECRUITING Louisville Kentucky 40202 United States Details
CHA Bundang Medical Center RECRUITING Seongnam-si Korea, Republic of Details
Asan Medical Center NOT_YET_RECRUITING Seoul Korea, Republic of Details
Samsung Medical Center RECRUITING Seoul Korea, Republic of Details
Seoul National University Hospital RECRUITING Seoul Korea, Republic of Details
Severance Hospital RECRUITING Seoul Korea, Republic of Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field